What's Going On With Eli Lilly Shares Friday?
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.
Eli Lilly and Co. (纽交所:LLY) 股票在周五下午出现增加的活跃度。以下是你需要了解的内容。
What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lilly with a price target of $1023. Despite this bullish outlook, options trading data from Benzinga shows a mixed sentiment among high-rolling investors, with 50% bearish and 41% bullish trades spotted. Significant options activity includes 11 call options totaling $569,034 and one put option amounting to $50,300.
何时发生：大摩资源lof维持对礼来公司的超配评级，目标价为1023美元。尽管持看涨看跌期权的高额投资者中意见不一，Benzinga的期权交易数据显示，50%看淡，41%看好。重要的期权交易活动包括11个看涨期权，总价值569,034美元以及一个看跌期权，总价值50,300美元。
Key Developments: Eli Lilly is making strides in the pharmaceutical sector with its GLP-1 treatments like Mounjaro and Zepbound, which have shown promising results in reducing obesity-related cancer risks. A recent study in JAMA Network highlighted the reduced risk of ten types of obesity-related cancers for patients using GLP-1 treatments compared to those on insulin or other diabetes medications.
重要进展：礼来公司在药品板块取得进展，其Mounjaro和Zepbound等GLP-1治疗药物已经显示出降低肥胖相关癌症风险的有希望结果。JAMA Network最近的一项研究强调，使用GLP-1治疗药物的患者相比于使用胰岛素或其他糖尿病药物的患者，患10种肥胖相关癌症的风险降低了。
Additionally, Eli Lilly's SURMOUNT-OSA phase 3 trials for tirzepatide demonstrated a significant reduction in the apnea-hypopnea index, showcasing potential benefits for treating obstructive sleep apnea.
另外，礼来公司的tirzepatide的SURMOUNt-OSA 3期试验证明减轻了睡眠呼吸暂停低通气指数，展示了治疗阻塞性睡眠呼吸暂停的潜在益处。
Analysts' Opinions: In the past month, several analysts have weighed in on Eli Lilly. B of A Securities maintained a Buy rating with a $1000 price target, while Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. BMO Capital also maintained an Outperform rating with a $1001 price target.
分析师的意见：在过去的一个月里，有几位分析师发表了对礼来公司的看法。B of A Securities维持买入评级，目标价为1000美元，而Cantor Fitzgerald的评级则下调为超配，目标价为885美元。BMO Capital还维持跑赢市场的评级，目标价为1001美元。
LLY Price Action: Eli Lilly shares were up by 1.91% at $915.23 according to Benzinga Pro.
LLY股价表现：根据Benzinga Pro，礼来公司的股价上涨了1.91%，报915.23美元。
Photo by rafapress on Shutterstock.
照片来自Shutterstock的rafapress。